Elocta

ประเทศ: สหภาพยุโรป

ภาษา: โรมาเนีย

แหล่งที่มา: EMA (European Medicines Agency)

ซื้อเลย

สารออกฤทธิ์:

efmoroctocog alfa

มีจำหน่ายจาก:

Swedish Orphan Biovitrum AB (publ)

รหัส ATC:

B02BD02

INN (ชื่อสากล):

efmoroctocog alfa

กลุ่มบำบัด:

hemostatice

พื้นที่บำบัด:

Hemofilia A

ข้อบ่งชี้ในการรักษา:

Tratamentul și profilaxia hemoragiilor la pacienții cu hemofilie A (deficit congenital de factor VIII). Elocta poate fi utilizat pentru toate grupele de vârstă.

สรุปสินค้า:

Revision: 12

สถานะการอนุญาต:

Autorizat

วันที่อนุญาต:

2015-11-18

แผ่นพับข้อมูลผู้ป่วย

                                60
B. PROSPECTUL
61
PROSPECT: INFORMAȚII PENTRU UTILIZATOR
ELOCTA 250 UI PULBERE ȘI SOLVENT PENTRU SOLUȚIE INJECTABILĂ
ELOCTA 500 UI PULBERE ȘI SOLVENT PENTRU SOLUȚIE INJECTABILĂ
ELOCTA 750 UI PULBERE ȘI SOLVENT PENTRU SOLUȚIE INJECTABILĂ
ELOCTA 1000 UI PULBERE ȘI SOLVENT PENTRU SOLUȚIE INJECTABILĂ
ELOCTA 1500 UI PULBERE ȘI SOLVENT PENTRU SOLUȚIE INJECTABILĂ
ELOCTA 2000 UI PULBERE ȘI SOLVENT PENTRU SOLUȚIE INJECTABILĂ
ELOCTA 3000 UI PULBERE ȘI SOLVENT PENTRU SOLUȚIE INJECTABILĂ
ELOCTA 4000 UI PULBERE ȘI SOLVENT PENTRU SOLUȚIE INJECTABILĂ
efmoroctocog alfa (factor VIII de coagulare recombinant)
CITIȚI CU ATENȚIE ȘI ÎN ÎNTREGIME ACEST PROSPECT ÎNAINTE DE A
ÎNCEPE SĂ UTILIZAȚI ACEST MEDICAMENT
DEOARECE CONȚINE INFORMAȚII IMPORTANTE PENTRU DUMNEAVOASTRĂ.
-
Păstrați acest prospect. S-ar putea să fie necesar să-l recitiți.
-
Dacă aveți orice întrebări suplimentare, adresați-vă medicului
dumneavoastră, farmacistului sau
asistentei medicale.
-
Acest medicament a fost prescris numai pentru dumneavoastră. Nu
trebuie să-l dați altor persoane.
Le poate face rău, chiar dacă au aceleași semne de boală ca
dumneavoastră.
-
Dacă manifestați orice reacții adverse, adresați-vă medicului
dumneavoastră, farmacistului sau
asistentei medicale. Acestea includ orice posibile reacții adverse
nemenționate în acest prospect.
Vezi pct. 4.
CE GĂSIȚI ÎN ACEST PROSPECT
1.
Ce este ELOCTA și pentru ce se utilizează
2.
Ce trebuie să știți înainte să utilizați ELOCTA
3.
Cum să utilizați ELOCTA
4.
Reacții adverse posibile
5.
Cum se păstrează ELOCTA
6.
Conținutul ambalajului și alte informații
1.
CE ESTE ELOCTA ȘI PENTRU CE SE UTILIZEAZĂ
ELOCTA conține substanța activă efmoroctocog alfa, un factor VIII
de coagulare recombinant, proteină de
fuziune Fc. Factorul VIII este o proteină produsă natural în
organism și este necesar pentru formarea
cheagurilor de sânge și oprirea sângerării.
ELOCTA este un medicament utilizat pentru tratamentul și prevenirea
s
                                
                                อ่านเอกสารฉบับเต็ม
                                
                            

สรุปลักษณะสินค้า

                                1
ANEXA I
REZUMATUL CARACTERISTICILOR PRODUSULUI
2
1.
DENUMIREA COMERCIALĂ A MEDICAMENTULUI
ELOCTA 250 UI pulbere și solvent pentru soluție injectabilă
ELOCTA 500 UI pulbere și solvent pentru soluție injectabilă
ELOCTA 750 UI pulbere și solvent pentru soluție injectabilă
ELOCTA 1000 UI pulbere și solvent pentru soluție injectabilă
ELOCTA 1500 UI pulbere și solvent pentru soluție injectabilă
ELOCTA 2000 UI pulbere și solvent pentru soluție injectabilă
ELOCTA 3000 UI pulbere și solvent pentru soluție injectabilă
ELOCTA 4000 UI pulbere și solvent pentru soluție injectabilă
2.
COMPOZIȚIA CALITATIVĂ ȘI CANTITATIVĂ
ELOCTA 250 UI pulbere și solvent pentru soluție injectabilă
Fiecare flacon conține nominal efmoroctocog alfa 250 UI.
ELOCTA conține aproximativ 83 UI/ml factor VIII de coagulare uman
recombinant efmoroctocog alfa
după reconstituire.
ELOCTA 500 UI pulbere și solvent pentru soluție injectabilă
Fiecare flacon conține nominal efmoroctocog alfa 500 UI. ELOCTA
conține aproximativ 167 UI/ml
efmoroctocog alfa recombinant după reconstituire.
ELOCTA 750 UI pulbere și solvent pentru soluție injectabilă
Fiecare flacon conține nominal efmoroctocog alfa 750 UI. ELOCTA
conține aproximativ 250 UI/ml
efmoroctocog alfa recombinant după reconstituire.
ELOCTA 1000 UI pulbere și solvent pentru soluție injectabilă
Fiecare flacon conține nominal efmoroctocog alfa 1000 UI. ELOCTA
conține aproximativ 333 UI/ml
efmoroctocog alfa recombinant după reconstituire.
ELOCTA 1500 UI pulbere și solvent pentru soluție injectabilă
Fiecare flacon conține nominal efmoroctocog alfa 1500 UI. ELOCTA
conține aproximativ 500 UI/ml
efmoroctocog alfa recombinant după reconstituire.
ELOCTA 2000 UI pulbere și solvent pentru soluție injectabilă
Fiecare flacon conține nominal efmoroctocog alfa 2000 UI. ELOCTA
conține aproximativ 667 UI/ml
efmoroctocog alfa recombinant după reconstituire.
ELOCTA 3000 UI pulbere și solvent pentru soluție injectabilă
Fiecare flacon conține nominal efmoroctoco
                                
                                อ่านเอกสารฉบับเต็ม
                                
                            

เอกสารเป็นภาษาอื่น

แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย บัลแกเรีย 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า บัลแกเรีย 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า เดนมาร์ก 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า เยอรมัน 26-02-2021
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย เอสโตเนีย 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า เอสโตเนีย 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า อังกฤษ 16-05-2018
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ฝรั่งเศส 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า อิตาลี 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ลัตเวีย 26-02-2021
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย ลิทัวเนีย 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ลิทัวเนีย 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ฮังการี 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า โปแลนด์ 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า โปรตุเกส 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า สโลวัก 26-02-2021
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย สโลวีเนีย 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า สโลวีเนีย 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ฟินแลนด์ 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า สวีเดน 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า นอร์เวย์ 26-02-2021
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย ไอซ์แลนด์ 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ไอซ์แลนด์ 26-02-2021
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย โครเอเชีย 26-02-2021
สรุปลักษณะสินค้า สรุปลักษณะสินค้า โครเอเชีย 26-02-2021

ค้นหาการแจ้งเตือนที่เกี่ยวข้องกับผลิตภัณฑ์นี้

ดูประวัติเอกสาร